Clinical trials
Lung Squamous Cell Carcinoma clinical trials
Below are recruiting lung squamous cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 579 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06107608Recruiting
Scan for tumors in lung cancer patients on immunotherapy
This study uses a special type of PET scan to look at specific cells in non-small cell lung cancer tumors that might help doctors understand how well immunotherapy treatments are working. If you are about to start immunotherapy for advanced lung cancer, you may be able to join.
BrusselsAges 18 years+ - NCT06911606RecruitingPhase 2
Serplulimab with chemotherapy before surgery for limited-stage small cell lung cancer
This trial tests adding an immunotherapy drug called serplulimab to standard chemotherapy before surgery for limited-stage small cell lung cancer (LS-SCLC). The goal is to see if this combination helps shrink the tumor and improve outcomes for patients who have not received prior treatment.
Guangzhou, GuangdongAges 18–75 - NCT07217301RecruitingPhase 3
Comparing TAK-928 to docetaxel for advanced lung cancer
This study tests a new drug called TAK-928 against the standard chemo docetaxel for people with advanced squamous non-small cell lung cancer. You may be able to join if you have already tried a checkpoint inhibitor and platinum chemotherapy, and your cancer has grown.
Jonesboro, ArkansasAges 18 years+ - NCT07181499RecruitingPhase 2
Chemotherapy with befotertinib for resistance to targeted lung cancer drugs
This trial tests a combination of chemotherapy and a targeted drug (befotertinib) for people with non-small cell lung cancer whose cancer has stopped responding to a common type of targeted therapy. It aims to see if this new sequence can help overcome resistance.
Guangzhou, GuangdongAges 18 years+ - NCT07138755RecruitingPhase 2
PD-1, chemo, and adaptive radiation for stage 3 lung cancer
This study tests if adding an immunotherapy drug (PD-1 inhibitor) to chemotherapy and specially planned radiation works better for stage 3 lung cancer that cannot be surgically removed. It may be an option if you have not had previous treatment for this cancer.
Changsha, HunanAges 18–75 - NCT07096882RecruitingPhase 1
SDTM001 injection after lung cancer surgery
This trial tests an injection called SDTM001 as an extra treatment after surgery for people with non-small cell lung cancer (NSCLC). It aims to see if it can help prevent the cancer from coming back.
Chengdu, SichuanAges 18–70 - NCT07105176RecruitingPhase 1
TIL therapy for advanced lung cancer after first-line treatment
This trial tests a new treatment using your own immune cells (called TILs) to fight advanced non-small cell lung cancer. The cells are taken from a tumor, multiplied in a lab, and given back to you to help your body attack the cancer.
Guangzhou, GuangdongAges 18–75 - NCT06970795RecruitingPhase 1
Study of SYS6040 for advanced solid tumors
This trial tests a new drug called SYS6040 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
Changchuan, JilinAges 18 years+ - NCT07089199RecruitingPhase 2
Treatment before surgery for stage 2–3 lung cancer
This study tests whether giving a combination of three medicines before surgery can help shrink tumors in people with stage 2 or 3 non-small cell lung cancer, potentially making surgery and recovery more effective. The medicines include an immunotherapy drug (tislelizumab), a targeted therapy (anlotinib), and a chemotherapy drug (nab-paclitaxel).
Jinan, ShandongAges 18–75 - NCT07087223RecruitingPhase 1/Phase 2
Study of vebreltinib plus furmonertinib for NSCLC with c-Met amplification
This trial tests a combination of two targeted therapies (vebreltinib and furmonertinib) for people with a specific type of advanced non-small cell lung cancer (NSCLC) that has a change called c-Met amplification and has stopped responding to earlier EGFR-targeted treatment. It aims to see if adding vebreltinib can help control the cancer.
Neimeng, NeimengAges 18 years+ - NCT05394831RecruitingPhase 1/Phase 2
Study of an EGFR-targeted drug for advanced lung cancer
This trial tests a new drug (JIN-A02) in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has specific EGFR mutations. It mainly checks whether the treatment is safe and tolerable, and how the body handles the drug, with possible benefit depending on your mutation type.
Orange, CaliforniaAges 18 years+ - NCT07082179RecruitingPhase 2
Immunotherapy plus chemotherapy for stage III lung cancer
This trial tests combining immunotherapy with chemotherapy for people with stage III non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink the tumor and improve outcomes.
NanjingAges 18–75 - NCT07070440RecruitingPhase 1/Phase 2
DZD6008 combination therapy for EGFR-mutated lung cancer
This trial tests a new combination treatment for people with advanced non-small cell lung cancer that has an EGFR mutation. It aims to see if this combination can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07052669RecruitingPhase 3
Shorter Chemo-Radiation Plus Immunotherapy for Stage III Lung Cancer
This trial tests a new schedule of chemo-radiation (fewer, stronger sessions) followed by an immunotherapy drug called tislelizumab. The goal is to see if this approach works better than the standard longer schedule for people with stage III lung cancer that can't be surgically removed.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT07016126RecruitingPhase 3
Study of D-BACE, chemo, and carlizumab for lung cancer
This trial tests a combination of a new drug (D-BACE), chemotherapy, and carlizumab for people with a certain type and stage of lung cancer that can be removed with surgery. It aims to see if this combination helps shrink tumors and improves outcomes.
Guangzhou, GuangdongAges 18–75 - NCT07003490Recruiting
Lung cancer surgery with removal of lymph nodes on the other side
This study looks at whether removing lymph nodes from the opposite side of the chest during surgery can help people with advanced lung cancer that has spread to the lymph nodes in the middle of the chest. It may offer a more thorough treatment for patients who are healthy enough for surgery.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06969612RecruitingPhase 1
New drug combo as first treatment for advanced lung cancer
This trial tests a new combination of three medicines (Golidocitinib, Tislelizumab, and chemotherapy) as the first treatment for advanced non-small cell lung cancer (NSCLC). It is designed for people whose tumors have at least 1% PD-L1 and who have not had any previous treatment for advanced disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06929936RecruitingPhase 2
Trilaciclib plus docetaxel for advanced lung cancer (second-line+)
This trial tests a new drug combination (trilaciclib plus docetaxel) for people with advanced lung cancer (NSCLC) whose cancer has progressed after at least one prior treatment. The goal is to see if adding trilaciclib helps the chemotherapy work better with fewer side effects.
Xiamen, FujianAges 18 years+ - NCT06956001RecruitingPhase 3
Testing firmanertinib vs chemo for first-line lung cancer with specific EGFR mutations
This trial compares a new targeted therapy pill (firmanertinib) to standard chemotherapy in people with advanced non-small cell lung cancer whose tumors have a specific EGFR mutation (PACC or L861Q). If you haven't had treatment for advanced disease and your cancer matches these mutations, this study may offer a more convenient oral option.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06951464RecruitingPhase 2
Targeted therapy before surgery for EGFR-mutated lung cancer
This trial tests a combination of two targeted drugs (BL-B01D1 and almonertinib) given before surgery to shrink EGFR-mutated lung cancer. The goal is to make surgery more effective and possibly improve long-term outcomes.
Chengdu, SichuanAges 18–75 - NCT06951646RecruitingPhase 2
Personalized treatment for advanced lung cancer with long response to first-line therapy
This trial tests a combination of ivonescimab and docetaxel for people with advanced non-small cell lung cancer who have had a long response (11-15 months without the cancer getting worse) to first-line immunotherapy. The goal is to see if adjusting treatment based on ctDNA-MRD levels can improve outcomes.
ChangshaAges 18–75 - NCT06930794RecruitingPhase 3
Study of Vebreltinib Plus Chemo for MET-Positive Lung Cancer
This trial tests a targeted drug (Vebreltinib) combined with standard chemotherapy in people with a specific type of advanced non-squamous lung cancer that has a MET gene change (amplification or overexpression). The goal is to see if this combination works better than chemo alone.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06276283RecruitingPhase 2
DZD9008 plus bevacizumab for EGFR-mutated advanced lung cancer
This trial tests a new targeted therapy (DZD9008) combined with a drug that blocks blood vessel growth (bevacizumab) for people with a specific type of advanced lung cancer (EGFR mutation). The goal is to see if this combination works better than current treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06897046RecruitingPhase 2
Study of Iparomlimab and Tuvonralimab for resectable lung cancer
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) before and after surgery for people with a certain type of lung cancer that can be removed. It aims to see if this treatment helps improve outcomes.
BeijingAges 18 years+
Hear when a new Lung Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung squamous cell carcinoma?
- Yes. Clin2 currently lists 579 recruiting lung squamous cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung squamous cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung squamous cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.